Why it Matters
The House is set to put the Department of Health and Human Services under the microscope this week on April 17, 2026, as the Trump administration's proposed budget would cut HHS funding by more than 12 percent. That means the budget for the NIH would be slashed by 40 percent and the one for FDA could be reduced by $409 million. At the same time, HHS is tasked with an expanded agenda under the Make America Healthy Again initiative. The April 17, 2026 hearing arrives as HHS Secretary Robert F. Kennedy Jr. faces mounting congressional scrutiny over the direction and management of the nation's largest health agency, and as dozens of organizations have spent the past year lobbying intensively on the policies at stake.
Budget Cuts Meet an Expanding Mandate
The central tension heading into the hearing is a familiar Washington paradox: the administration is proposing to do more with less. The White House budget proposal, reported by AJMC, would consolidate NIH down to eight centers while cutting its funding by 40 percent. The FDA faces a $409 million reduction even as it is being asked to ramp up inspections and enforcement under the MAHA agenda. STAT News reported that the White House is also attempting to revive Kennedy's proposed Administration for a Healthy America — an agency Congress declined to fund in the prior budget cycle.
Meanwhile, HHS has not been standing still organizationally. In April, Secretary Kennedy announced enhancements to his management team aimed at accelerating what the department describes as President Trump's "Great Healthcare Plan." The restructuring, according to Medical Economics, is designed to consolidate divisions, eliminate redundancies, and leverage AI and telemedicine — a vision Kennedy has been pressing even as critics challenge his stewardship.
Kennedy's Leadership Under Fire
Senate Democrats have been sharpening their attacks on Kennedy's record. Senator Ron Wyden (D-OR), as reported by COSSA, recently highlighted a report titled "Costs, Chaos, and Corruption: 203 Days of Robert F. Kennedy Jr.'s Disastrous Leadership" during Senate Finance Committee proceedings. That Senate activity serves as a direct precursor to the House examination scheduled for April 17.
Operational problems have compounded the political ones. Federal News Network reported that HHS accumulated a backlog of 9,000 medical telework accommodation requests, prompting the CDC to ease restrictions that department officials and the Office of Personnel Management suggested may have been overly restrictive. The workforce management challenges add a layer of administrative accountability to what the hearing will examine.
Lobbying Disclosures
The lobbying landscape surrounding the Department of Health and Human Services hearing reflects the breadth of constituencies with skin in the game. An analysis of lobbying disclosure filings from April 2025 through April 2026 identified 25 relevant filings spanning research universities, disease advocacy organizations, hospital systems, and federal contractors.
On the research funding front, the University of Chicago filed in both the fourth quarter of 2025 and first quarter of 2026 — spending $50,000 each quarter — on issues including Labor-HHS-Defense appropriations. The National Kidney Foundation filed in the first quarter of 2025, spending $50,000 on appropriations for HHS, NIH, and CDC, specifically to support kidney disease activities.
Disease advocacy groups have been particularly active. The Cystic Fibrosis Foundation spent $300,000 in the second quarter of 2025 on a filing that addressed the One Big Beautiful Bill Act alongside HHS, FDA, CDC, and NIH agency funding. Parent Project Muscular Dystrophy filed in both the third and fourth quarters of 2025, spending $30,000 per quarter on NIH, CDC, FDA, Medicaid, and Department of Defense issues tied to muscular dystrophy research.
Cincinnati Children's Hospital Medical Center filed across multiple quarters with disclosures that read like a roadmap of the hearing's likely agenda items: HHS reform, vaccines, CDC reform, NIH reform, reconciliation, Medicaid, pediatric research, and the 340B drug pricing program. Their second quarter 2025 filing totaled $35,786, their third quarter $34,890, and their fourth quarter $30,780.
On the Medicaid side, Haymarket Center — a substance use treatment provider — filed in the second quarter of 2025 ($20,000) and third quarter of 2025 ($20,000) on the Medicaid Institution for Mental Disease exclusion, opioid legislation, and Medicaid managed care regulations.
Federal contractors have also been engaged. CoventBridge (USA) Inc. filed in the Second Quarter of 2025 ($10,000) and Third Quarter of 2025 ($40,000) on issues related to its federal contracts with HHS and the USDA.
The Bottom Line
The hearing, covers the full scope of HHS policy priorities — a mandate broad enough to encompass the budget fight, the MAHA restructuring agenda, vaccine policy, Medicaid, and the operational management controversies that have trailed Kennedy's tenure.
Just days before the hearing, HHS's Health Resources and Services Administration announced more than $135 million in new funding for nutrition services and rural health — a concrete data point the department can point to as evidence of programmatic delivery even as the overall budget picture tightens.
The lobbying filings, the Senate hearings, the budget battles, and the internal management struggles all converge on a single question House members will be pressing: whether HHS under Kennedy's leadership has the capacity and the coherence to execute an ambitious health agenda while absorbing significant funding reductions across its core scientific and regulatory agencies.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article